These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9804512)

  • 1. Positive panel reactive antibody titers in patients bridged to transplantation with a mechanical assist device: risk factors and treatment.
    Tsau PH; Arabía FA; Toporoff B; Paramesh V; Sethi GK; Copeland JG
    ASAIO J; 1998; 44(5):M634-7. PubMed ID: 9804512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peri-operative alemtuzumab (Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support.
    Lick SD; Vaidya S; Kollar AC; Boor PJ; Vertrees RA
    J Heart Lung Transplant; 2008 Sep; 27(9):1036-9. PubMed ID: 18765198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Success rates of long-term circulatory assist devices used currently for bridge to heart transplantation.
    Arabia FA; Smith RG; Rose DS; Arzouman DA; Sethi GK; Copeland JG
    ASAIO J; 1996; 42(5):M542-6. PubMed ID: 8944938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab.
    Lick SD; Beckles DL; Piovesana G; Vaidya S; Indrikovs A; Barbagelata NA; Valentine V
    Ann Thorac Surg; 2011 Oct; 92(4):1428-34. PubMed ID: 21855854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA and MICA allosensitization patterns among patients supported by ventricular assist devices.
    Askar M; Hsich E; Reville P; Nowacki AS; Baldwin W; Bakdash S; Daghstani J; Zhang A; Klingman L; Smedira N; Moazami N; Taylor DO; Starling RC; Gonzalez-Stawinski G
    J Heart Lung Transplant; 2013 Dec; 32(12):1241-8. PubMed ID: 24075503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing HLA sensitization in implantable LVAD recipients.
    Massad MG; Cook DJ; Schmitt SK; Smedira NG; McCarthy JF; Vargo RL; McCarthy PM
    Ann Thorac Surg; 1997 Oct; 64(4):1120-5. PubMed ID: 9354538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with the Novacor ventricular assist system. Bridge to transplantation and the transition to permanent application.
    McCarthy PM; Portner PM; Tobler HG; Starnes VA; Ramasamy N; Oyer PE
    J Thorac Cardiovasc Surg; 1991 Oct; 102(4):578-86; discussion 586-7. PubMed ID: 1921434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between bridging with ventricular assist device on rejection after heart transplantation.
    Pamboukian SV; Costanzo MR; Dunlap S; Rayburn B; Westfall AO; You ZY; Hung E; McLeod M; Heroux A
    J Heart Lung Transplant; 2005 Mar; 24(3):310-5. PubMed ID: 15737758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device.
    Baran DA; Gass AL; Galin ID; Zucker MJ; Arroyo LH; Goldstein DJ; Prendergast T; Lubitz S; Courtney MC; Correa R; Chan M; Spielvogel D; Lansman SL
    J Heart Lung Transplant; 2005 Nov; 24(11):1886-90. PubMed ID: 16297796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation?
    Kobashigawa JA; Sabad A; Drinkwater D; Cogert GA; Moriguchi JD; Kawata N; Hamilton MA; Hage A; Terasaki P; Laks H
    Circulation; 1996 Nov; 94(9 Suppl):II294-7. PubMed ID: 8901763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA sensitization in ventricular assist device recipients: does type of device make a difference?
    Kumpati GS; Cook DJ; Blackstone EH; Rajeswaran J; Abdo AS; Young JB; Starling RC; Smedira NG; McCarthy PM
    J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1800-7. PubMed ID: 15173739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates.
    Zimpfer D; Zrunek P; Roethy W; Czerny M; Schima H; Huber L; Grimm M; Rajek A; Wolner E; Wieselthaler G
    J Thorac Cardiovasc Surg; 2007 Mar; 133(3):689-95. PubMed ID: 17320566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients.
    Drakos SG; Kfoury AG; Long JW; Stringham JC; Fuller TC; Nelson KE; Campbell BK; Gilbert EM; Renlund DG
    Ann Thorac Surg; 2006 Sep; 82(3):889-93. PubMed ID: 16928502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Intraoperative Blood Product Use During Heart Transplantation in Patients Bridged with Impella 5.5 versus Durable Left Ventricular Assist Devices.
    Shapiro AB; Fritz AV; Kiley S; Sharma S; Patel P; Heckman A; Martin AK; Goswami R
    J Cardiothorac Vasc Anesth; 2024 Nov; 38(11):2567-2575. PubMed ID: 39003127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices.
    Kamdar F; John R; Eckman P; Colvin-Adams M; Shumway SJ; Liao K
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):575-81. PubMed ID: 23321132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis.
    McIntyre JA; Higgins N; Britton R; Faucett S; Johnson S; Beckman D; Hormuth D; Fehrenbacher J; Halbrook H
    Transplantation; 1996 Sep; 62(5):691-3. PubMed ID: 8830839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions.
    Drakos SG; Stringham JC; Long JW; Gilbert EM; Fuller TC; Campbell BK; Horne BD; Hagan ME; Nelson KE; Lindblom JM; Meldrum PA; Carlson JF; Moore SA; Kfoury AG; Renlund DG
    J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1612-9. PubMed ID: 17532964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is bridging to transplantation with a left ventricular assist device a risk factor for transplant coronary artery disease?
    Radovancevic B; Golino A; Vrtovec B; Thomas CD; Radovancevic R; Odegaard P; van Rossem CC; Gaemers SJ; Vaughn WK; Smart FW; Frazier OH
    J Heart Lung Transplant; 2005 Jun; 24(6):703-7. PubMed ID: 15949730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes.
    Alba AC; Tinckam K; Foroutan F; Nelson LM; Gustafsson F; Sander K; Bruunsgaard H; Chih S; Hayes H; Rao V; Delgado D; Ross HJ
    J Heart Lung Transplant; 2015 May; 34(5):685-92. PubMed ID: 25638296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation.
    Bull DA; Reid BB; Selzman CH; Mesley R; Drakos S; Clayson S; Stoddard G; Gilbert E; Stehlik J; Bader F; Kfoury A; Budge D; Eckels DD; Fuller A; Renlund D; Patel AN
    J Thorac Cardiovasc Surg; 2010 Jul; 140(1):169-73. PubMed ID: 20451930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.